Statistics about Health, Pharma & Medtech in United States
Statistics
- U.S. prescription drug prices opinions in 2019 by attitude toward Trump
- Most commonly used complementary health approaches share in the U.S. 2002 and 2012
- Number of U.S. adult users of complementary health approaches in 2012, by ethnicity
- Usage of complementary health approaches in the U.S. 2002 and 2012 by ethnicity
- U.S. adult's most commonly used nonvitamin, nonmineral dietary supplements 2012
- Number of U.S. adults who used nonvitamin, nonmineral dietary supplements 2012
- Clinical trials starts for new type 2 diabetes drugs U.S. 2008-2017
- Obesity drugs clinical pipeline U.S. 2018, by type and phase
- Clinical trial starts for new obesity drugs U.S. 2008-2017
- Prescription drug price development in the U.S. by select drug 2010-2017
- Type 2 diabetes clinical trial success rates U.S. 2006-2015, by phase and indication
- High availability of heroin in U.S. 2010 and 2017, by region
- U.S. hospitals with select levels of medication price markups 2017
- Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Expedited drug approvals by firms from California 2014-2019
- Drug products in the pipeline in California 2020, by therapeutic area
- Time from R&D start to approval of select cancer drugs 2017
- Total R&D costs of select cancer drugs 2017
- Total R&D costs including costs of capital for select cancer drugs 2017
- Obesity clinical trial success rates for novel drugs U.S. 2006-2015 by phase
- Revenue since approval for select cancer drugs 2017
- U.S. number of adult users of complementary health approaches in 2002 and 2012
- U.S. orphan drugs with patents and orphan drug exclusivity as of 2018
- R&D expenditure of new therapeutic drugs 2009-2018
- Annual percentage change of DTCA expenditure for Eliquis U.S. 2013-2018
- Share of generic drug purchases in the U.S. by buyer consortium 2018
- Total U.S. hyaluronic acid raw material market size 2014-2024
- U.S. hyaluronic acid raw material market size 2014-2024, by application
- Total U.S. OTC hyaluronic acid market size 2014-2024
- Leading specialty therapy drugs U.S. - net price change 2017-2019
- Number of persons misusing select Rx drug types in U.S. 2017, by age
- U.S. marijuana entrepreneur's outlook for next 12 months in 2016 by sector
- U.S. opinions on the effectiveness of homeopathy 2015, by age
- U.S. opinions on the effectiveness of select alternative medicines 2015
- Annual percentage change of DTCA expenditure for Namenda XR in the U.S. 2013-2018
- Share of U.S. opioid ED visits prescribed naloxone or buprenorphine 2019-2021
- Rate of misuse of select prescription drug types in U.S. 2017, by age
- U.S import value of Chinese antibiotic products 2019
- CHina's share in U.S imports of antibiotic products 2019
- Number of patients with at least one opioid prescription U.S. 2014-2018
- Select antibiotic prescription trends before and after generic entry U.S. 2000-2012
- Total U.S. OTC hyaluronic acid market size by application 2014-2024
- Top CPDs dispensed in billion dosage units in the U.S. 2011-2016
- Botanical IND applications to the FDA 2002-2016
- Participation in clinical trials recommended by a doctor among U.S. adults 2021
- Revenue as a part of R&D spending for select cancer drugs 2017
- Clinical trial success rates by therapeutic area 2020
- Perceptions of medical marijuana/cannabis use in the U.S. in 2019
- Price reduction of drugs after loss of exclusivity in the U.S. 2015
- Estimated sales of major generic introductions in U.S. 2016
- Drug overdose male death rates in the U.S. 2018, by age
- U.S. population with 5 or more prescriptions within 30 days by age 1988-2018
- Migraine treatment out-of-pocket spending among U.S. patients 2016
- Percentage of U.S. respondents who used a sleep aid remedy in the past year 2015
- Prescription and nonprescription sleep aid use in the U.S. by type 2015
- Most commonly purchased OTC sleep remedies in the U.S. 2015
- Top specialty therapy drugs in the U.S. by percent of total spending 2016
- Number of FDA approved NMEs, 2009-2018, by size of drug owner
- Number of FDA approved NMEs, 2009-2018, by size of drug originator
- Total U.S. population with 5 or more prescriptions within 30 days 1988-2018
- Prescriptions number - gastrointestinal products in the U.S. 2009-2021
- Top internal analgesic brands by ad count in U.S. 2014-2015 and 2015-2016
- Leading specialty therapy drugs in the U.S. by PMPY spending 2016
- Share of prescription opioid abusers in the U.S. 2011-2015, by age
- Share of costs of prescription opioid overdose, abuse and addiction in the U.S. 2013
- Consumers willingness to financing drug prescriptions U.S. 2015
- Leading traditional therapy drugs in the U.S. by percent of total spending 2016
- Leading traditional therapy drugs in the U.S. - unit cost change 2016
- Support for U.S. marijuana legalization 2010 vs. 2018, by region
- Sales forecast for eye care product Restasis in U.S. 2014-2025
- U.S. population with 5 or more prescriptions within 30 days by gender 1988-2018
- Novel pain drug clinical trials success rates U.S. 2006-2015, by phase
- Alaska's medical cannabis spending 2018-2024
- U.S. addiction medication clinical trials in 2018, by phase and indication
- U.S. prescription drug prices opinions in 2019 by political orientation
- U.S. prescription drug prices opinions 2019
- Total trend for traditional therapy areas in the U.S. 2019
- Adjusted and unadjusted generic prescription growth in U.S. 2014-2018
- Projected sales at risk due to patent expiry 2014-2023
- Leading traditional therapy drugs in the U.S. by PMPY spending 2016
- DTMs used by U.S. patients diagnosed with MS 2016 by administration route
- Washington D.C.'s medical cannabis spending 2018-2024
- Colorado's medical cannabis spending 2018-2024
- U.S. population with 3 or more prescriptions within 30 days by gender 1988-2018
- Maine's medical cannabis spending 2018-2024
- Massachusetts' medical cannabis spending 2018-2024
- Percentage of treatments used by US patients diagnosed with MS 2016
- Nevada's medical cannabis spending 2018-2024
- Price growth of selected pharmaceutical products in the U.S. 2013 and 2014
- Percentage of Rx drugs prescribed to multiple sclerosis patients 2013
- Total U.S. population with usage of prescription drugs within 30 days 1988-2018
- U.S. population with usage of Rx drugs within 30 days by gender 1988-2018
- Total U.S. population with 3 or more prescriptions within 30 days 1988-2018
- Views on medical cannabis use in U.S. adults by ethnicity 2019
- Views on medical cannabis use in U.S. adults 2019, by region
- Rx oral solid opioids market share for morphine equivalents U.S. 2017, by drug
- U.S. consumers' out-of-pocket costs for Harvoni as of 2020, by program and coverage
- Per patient cost of medication non-adherence by select disease per year 2017
- Number of ANDA approvals in U.S. 2015-2017, by type
- Total market size for biomarkers in the United States 2015-2024